Where does Sarepta Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	——	——	-$248.39M-764%
Depreciation and amortization	$45.14M+15.9%	$44.52M+18.0%	$49.72M+28.7%	$41.08M+3.3%	$38.96M-6.9%
Stock-based compensation	$111.37M-39.8%	$123.4M-33.0%	$143.06M-20.7%	$171.58M-7.3%	$185.04M+1.7%
Net cash from operating activities	——	——	——	——	——
Capital expenditures	$60.4M-59.2%	$101.97M-25.5%	$136.46M+15.7%	$150.79M+36.7%	$148.16M+49.6%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of debt	——	——	——	——	——
Repayments of debt	——	——	——	——	——
Net cash from financing activities	-$180.57M-257%	-$168.34M-235%	-$80.15M-203%	$51.4M-35.3%	$115.14M+154%
Net increase (decrease) in cash	——	——	——	——	-$186.42M+58.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sarepta Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.